Company intelligence / Profile preview

Xiaomo Biotech Limited

Hong Kong, N/A, Hong Kong SARxiaomobio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Xiaomo Biotech has developed a proprietary pro-siRNA platform that enables cost-effective, large-scale biomanufacturing of siRNAs using engineered bacteria. The company is developing first-in-class RNAi medicines and pesticides to address unmet needs in gene therapy and agriculture. No clinical trial results have been published yet; the company remains at the preclinical/R&D stage with ongoing expansion into mainland China.

Therapeutic areas: OtherRare Diseases
Modalities: Small interfering RNAs (siRNAs)RNA interference (RNAi) therapeutics
Industry: Biotech

Beyond the preview

Go deeper on Xiaomo Biotech Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaomo Biotech Limited.

Explore the full profile